5.06 USD
▲+0.05+1.00%
盘后 5.00 -1.19%
2026-09-15
市值
$1.65B
市盈率
—
EPS
-0.41
股息率
—
52 周区间
2.71 – 7.30
成交量
5.15M
Beta
1.17
目标价
13.33
52W 低 2.7152W 高 7.30
价格走势
公司简介
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-...